Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: prometheusbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $160.00 → $200.00 | Buy → Hold | Jefferies |
| 7/20/2022 | $51.00 | Buy | Goldman |
| 6/10/2022 | $53.00 | Overweight | Piper Sandler |
| 3/10/2022 | $50.00 → $52.00 | Outperform | Credit Suisse |
| 3/10/2022 | $42.00 → $53.00 | Overweight | Wells Fargo |
| 3/10/2022 | $47.00 → $55.00 | Outperform | SVB Leerink |
| 2/11/2022 | $62.00 | Buy | BTIG |
| 12/13/2021 | $46.00 | Outperform | RBC Capital Mkts |
| 12/8/2021 | $42.00 | Overweight | Wells Fargo |
| 12/8/2021 | $35.00 → $50.00 | Perform → Outperform | Oppenheimer |
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)
25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)
S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)
S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)
POSASR - Prometheus Biosciences, Inc. (0001718852) (Filer)
8-K - Prometheus Biosciences, Inc. (0001718852) (Filer)
8-K - Prometheus Biosciences, Inc. (0001718852) (Filer)
DEFA14A - Prometheus Biosciences, Inc. (0001718852) (Filer)
DEFA14A - Prometheus Biosciences, Inc. (0001718852) (Filer)
8-K - Prometheus Biosciences, Inc. (0001718852) (Filer)
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro
Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn's disease and other autoimmune conditions Prometheus Biosciences' comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. "At Merck, we are committed to delivering on our purpose to save and improv
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET. A live and archived webcast of the fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website. About Prometheus Biosciences Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneerin
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – – Initiated a third Phase 2 of PRA023 into SSc-ILD, demonstrating pipeline-in-a-product candidate potential for the program – – Expanded clinical pipeline with advancement of PRA052, a potentially first-in-class monoclonal antibody blocking CD30L, into Phase 1 – – Strong cash position of >$700M following full completion of recent financing – SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision
- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3rd - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented on March 4th - SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced two oral presentations on PRA023 at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), taking place in Copenhagen, Denmark, March 1- 4
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET. A live and archived webcast of the fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website. About Prometheus Biosciences Prometheus Biosciences, Inc. is a clinical-stage biotechnol
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 3:45 p.m. PST. The presentation will be webcast live on the Events & Webcasts page on the Investor section of Prometheus' website and will be avai
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in the offering are to be sold by Prometheus. The gross proceeds to Prometheus from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to b
Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo
Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced the appointment of Fred Hassan to its Board of Directors. "We're honored to have a highly accomplished industry titan like Fred join our Board at this pivotal time," said Mark McKenna, President and CEO of Prometheus. "Fred's wealth of experience over the last thirty years as an investor, board member,
Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously
Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00
Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00
Credit Suisse reiterated coverage of Prometheus Biosciences with a rating of Outperform and set a new price target of $52.00 from $50.00 previously
Wells Fargo reiterated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00 from $42.00 previously
SVB Leerink reiterated coverage of Prometheus Biosciences with a rating of Outperform and set a new price target of $55.00 from $47.00 previously
BTIG initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $62.00
RBC Capital Mkts initiated coverage of Prometheus Biosciences with a rating of Outperform and set a new price target of $46.00
Wells Fargo initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $42.00
Oppenheimer upgraded Prometheus Biosciences from Perform to Outperform and set a new price target of $50.00 from $35.00 previously
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)
In a rare move to block a large pharma deal, the U.S. Federal Trade Commission would sue to stop Amgen Inc's (NASDAQ:AMGN) $28 billion takeover of Horizon Therapeutics PLC (NASDAQ:HZNP). Reuters reported that the FTC said Amgen could use its solid position to pressure insurance companies and pharmacy benefit managers into favorable terms for Horizon's two key products - thyroid eye disease treatment Tepezza and gout drug Krystexxa. FTC Bureau of Competition Director Holly Vedova, in the Reuters report, called the lawsuit "the FTC's first challenge to a pharmaceutical merger in recent memory." "Rampant consolidation in the pharmaceutical industry has given powerful companies a pass to exor
RBC Capital analyst Gregory Renza maintains Prometheus Biosciences (NASDAQ:RXDX) with a Sector Perform and maintains $200 price target.
Upgrades For Tabula Rasa HealthCare Inc (NASDAQ:TRHC), SVB Leerink upgraded the previous rating of Market Perform to Outperform. Tabula Rasa HealthCare earned $0.02 in the first quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Tabula Rasa HealthCare shows a 52-week-high of $6.69 and a 52-week-low of $2.09. Moreover, at the end of the last trading period, the closing price was at $5.52. According to Maxim Group, the prior rating for Paltalk Inc (NASDAQ:PALT) was changed from Hold to Buy. Paltalk earned $0.08 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Paltalk shows a 52-week-high of $4.60 and a 52-wee
Jefferies analyst Michael Yee downgrades Prometheus Biosciences (NASDAQ:RXDX) from Buy to Hold and raises the price target from $160 to $200.
It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S. stock market, as represented by the SPDR S&P 500 ETF (NYSE:SPY), rising about 1.3% during the month, but notable differences emerged among different industries. Top 5 Performing US Industry ETFs in April ETF Name Month-to-date % chg YTD % chg SPDR S&P Biotech ETF (NYSE:XBI) 5.06% -3.54% SPDR S&P Homebuilders ETF (NYSE:XHB) 4.66% 17.57% SPDR S&P Health Care Equipment ETF (NYSE:XHE) 4.39% 8.71%
Upgrades Canaccord Genuity upgraded the previous rating for Sigma Lithium Corp (NASDAQ:SGML) from Speculative Buy to Buy. The current stock performance of Sigma Lithium shows a 52-week-high of $40.30 and a 52-week-low of $12.75. Moreover, at the end of the last trading period, the closing price was at $38.78. Wells Fargo upgraded the previous rating for Danaher Corp (NYSE:DHR) from Equal-Weight to Overweight. In the fourth quarter, Danaher showed an EPS of $2.87, compared to $2.69 from the year-ago quarter. The current stock performance of Danaher shows a 52-week-high of $303.81 and a 52-week-low of $234.52. Moreover, at the end of the last trading period, the closing price was at $255.75
Wells Fargo analyst Chris Carey downgrades Prometheus Biosciences (NASDAQ:RXDX) from Overweight to Equal-Weight and raises the price target from $164 to $200.
Credit Suisse analyst Tiago Fauth downgrades Prometheus Biosciences (NASDAQ:RXDX) from Outperform to Neutral and raises the price target from $139 to $200.
RBC Capital analyst Gregory Renza downgrades Prometheus Biosciences (NASDAQ:RXDX) from Outperform to Sector Perform and raises the price target from $140 to $200.
Piper Sandler analyst Yasmeen Rahimi downgrades Prometheus Biosciences (NASDAQ:RXDX) from Overweight to Neutral and raises the price target from $138 to $200.